

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

JDH 京东健康

JD Health International Inc.

京东健康股份有限公司

(A company incorporated in the Cayman Islands with limited liability)

(Stock Codes: 6618 (HKD counter) and 86618 (RMB counter))

INSIDE INFORMATION

UNAUDITED UPDATE ON THE 2024 THIRD QUARTER

This announcement is issued by JD Health International Inc. (the “**Company**” or “**JD Health**”, and together with its subsidiaries and consolidated affiliated entities, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Business Update

- During the three months ended September 30, 2024 (the “**Reporting Period**”), JD Health deepened its cooperation with pharmaceutical companies, with various new drugs debuting on JD Pharmacy. These included Beichangping[®] (Cofroglipin Tablets), the world’s first ultra-long-acting glucose-lowering drug developed by Haisco; FABHALTA[®], a rare disease drug developed by Novartis; and Atozet[®], a lipid-lowering drug developed by Organon. JD Health also leveraged its supply chain advantages to help pharmaceutical companies establish efficient drug distribution systems and innovative digital business models. Furthermore, Merck’s flagship store was officially launched on JD Health during the Reporting Period. We will deepen our collaboration with Merck in areas such as market expansion and online patient management, continuously improving medication accessibility and convenience for patients.
- During the Reporting Period, JD Health advanced its service model innovation, enabling online payment services through individual medical insurance accounts in 10 cities, including Guangzhou, Shenzhen, and Chengdu. As of September 30, 2024, we have cumulatively introduced online payment services in 12 cities with access to nearly 2,000 medical insurance-designated retail pharmacies, covering a population of over 100 million.

- During the Reporting Period, JD Health continued to refine the online medical service experience by launching a variety of fast-testing services, creating a closed-loop online medical service model integrating “consultation + examination + medical and healthcare product sales.” Doctors practiced on JD Health Online Hospital order medical tests for users, after which users schedule an at-home nurse visit to complete sample collection and testing. Once testing is complete, users receive test results online and can purchase medication based on the diagnosis. During the Reporting Period, we launched more than 100 types of at-home testing services and 27 home care services, covering 14 cities nationwide, including Beijing, Shanghai, Guangzhou and Shenzhen, further enhancing our one-stop service experience.

Unaudited Financial Information

The Company is pleased to announce the unaudited revenue, operating income and profit of the Group for the three months ended September 30, 2024 together with comparative figures for the corresponding period of 2023:

	Three months ended September 30,		
	2024	2023	Change
	<i>RMB'000</i>	<i>RMB'000</i>	(%)
	(Unaudited)	(Unaudited)	
Revenue	13,302,050	11,585,424	14.8
Operating income ⁽¹⁾	551,733	174,606	216.0
Non-IFRS operating income ⁽²⁾	861,809	744,854	15.7
Profit for the period	932,208	298,548	212.2
Non-IFRS profit for the period ⁽³⁾	1,335,616	949,926	40.6

(1) Operating income consists of gross profit deducting fulfillment expenses, selling and marketing expenses, research and development expenses, general and administrative expenses, and impairment losses under expected credit loss model, net of reversal, except for impairment losses of a certain asset that is non-operating in nature.

(2) We define “non-IFRS operating income” as operating income for the period, excluding share-based payment expenses for the period. We exclude this item because it is non-operating in nature, not indicative of our core operating results and business outlook, and it does not generate any cash outflows.

(3) We define “non-IFRS profit” as profit for the period, excluding share-based payment expenses, fair value changes for financial assets and liabilities at fair value through profit or loss except for wealth management products, impairment losses of a certain asset, and tax effects on non-IFRS adjustments for the period. We exclude these items because they are non-operating in nature, not indicative of our core operating results and business outlook, or they do not generate any cash outflows.

The above information is based on the board (the “**Board**”) of directors (the “**Directors**”) of the Company’s preliminary review of the internal data currently available and gathered by the Company only and is not intended to be a comprehensive statement of the Group’s financial result. The said information and data have not been audited or reviewed by the Company’s auditors and may be subject to change and adjustment.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
JD Health International Inc.
Mr. Enlin Jin
Executive Director

Hong Kong, November 14, 2024

As of the date of this announcement, the Board comprises Mr. Enlin Jin as the executive Director, Mr. Richard Qiangdong Liu and Mr. Qingqing Yi as non-executive Directors, and Ms. Ling Li, Dr. Jiyu Zhang, Mr. Xingyao Chen, Mr. Ying Wu and Professor George Lau as independent non-executive Directors.